Dr. Reddy's takes 9.7% stake in Coya Therapeutics (COYA) via subsidiary

Rhea-AI Filing Summary

Dr. Reddy's Laboratories reported beneficial ownership of 2,272,727 shares of Coya Therapeutics, Inc. common stock, representing 9.7% of the class. The shares are directly held by Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories Limited are disclosed as potentially deemed beneficial owners through the corporate chain.

The filing cites 20,924,456 shares outstanding as of November 10, 2025 and 2,522,727 shares issued and outstanding as of January 29, 2026 in related issuer reports; the ownership table shows sole voting and dispositive power for the 2,272,727 shares.

Insights

Corporate Governance Attorney

Filing documents a passive large-holder position with corporate attribution.

The Schedule 13G lists 2,272,727 shares and 9.7% ownership, with sole voting and dispositive power attributed to Dr. Reddy's Laboratories, Inc. The filing also clarifies the subsidiary/parent relationships that may result in deemed beneficial ownership by parent entities.

Key dependency is the issuer-reported share counts: 20,924,456 shares outstanding as of November 10, 2025 and 2,522,727 shares issued and outstanding as of January 29, 2026. Subsequent disclosures will determine any change in filing status or reporting obligations.

Institutional Ownership Analyst

Position size is material for a single holder but appears as a passive Schedule 13G disclosure.

The filing shows sole voting and dispositive power for 2,272,727 shares, listed as 9.7% of the class. The ownership is presented as holdings of a corporate subsidiary with potential attribution up the corporate chain.

Impact depends on whether holdings change; current disclosure signals a notable passive stake rather than an active takeover intent. Future amendments would reveal any shifts in intent or ownership percentage.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Coya Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

01/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

1

Names of Reporting Persons

Dr. Reddy's Laboratories, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW JERSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,272,727.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,272,727.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,272,727.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.7 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q ("Form 10-Q") filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.

SCHEDULE 13G

CUSIP Number(s):

1

Names of Reporting Persons

Dr. Reddy's Laboratories SA

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,272,727.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,272,727.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,272,727.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.7 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Note to Rows 5, 7 and 9: Represents shares directly held by Dr. Reddy's Laboratories, Inc., a wholly-owned subsidiary of Dr. Reddy's Laboratories SA. Dr. Reddy's Laboratories SA is a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited. As a result, each of Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories SA may each be deemed to beneficially own the shares held by Dr. Reddy's Laboratories Inc. Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.

SCHEDULE 13G

CUSIP Number(s):

1

Names of Reporting Persons

Dr. Reddy's Laboratories Limited

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

INDIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,272,727.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,272,727.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,272,727.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.7 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: Note to Rows 5, 7 and 9: Represents shares directly held by Dr. Reddy's Laboratories, Inc., a wholly-owned subsidiary of Dr. Reddy's Laboratories SA. Dr. Reddy's Laboratories SA is a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited. As a result, each of Dr. Reddy's Laboratories Limited and Dr. Reddy's Laboratories SA may each be deemed to beneficially own the shares held by Dr. Reddy's Laboratories Inc. Note to Row 11: Based upon 20,924,456 shares of Common Stock of the Issuer outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025 and 2,522,727 shares of Common Stock of the Issuer issued and outstanding as of January 29, 2026, as reported in the Issuer's Form 8-K filed with the SEC on January 30, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coya Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 5850 San Felipe St., Suite 500, Houston, TX 77057
Item 2.
(a)	Name of person filing: Dr. Reddy's Laboratories, Inc. Dr. Reddy's Laboratories SA Dr. Reddy's Laboratories Limited
(b)	Address or principal business office or, if none, residence: Dr. Reddy's Laboratories, Inc. - 600 College Road East, Suite 4000, Princeton, NJ 08540 Dr. Reddy's Laboratories SA - Grosspeter Tower Grosspeteranlage 294052 Basel, Switzerland Dr. Reddy's Laboratories Limited - 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India
(c)	Citizenship: Dr. Reddy's Laboratories, Inc. - New Jersey Dr. Reddy's Laboratories SA - Switzerland Dr. Reddy's Laboratories Limited - Republic of India
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 22407B108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Dr. Reddy's Laboratories, Inc. is the record owner of 2,272,727 shares of Common Stock of the Issuer. Dr. Reddy's Laboratories, Inc. is a wholly-owned subsidiary of Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories SA is a wholly-own subsidiary of Dr. Reddy's Laboratories Limited. Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories, Inc. may be deemed to beneficially own these securities.
(b)	Percent of class: 9.7%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Dr. Reddy's Laboratories, Inc. - 2,272,727 Dr. Reddy's Laboratories SA - 2,272,727 Dr. Reddy's Laboratories Limited - 2,272,727
	(ii) Shared power to vote or to direct the vote: Dr. Reddy's Laboratories, Inc. - None Dr. Reddy's Laboratories SA - None Dr. Reddy's Laboratories Limited - None
	(iii) Sole power to dispose or to direct the disposition of: Dr. Reddy's Laboratories, Inc. - 2,272,727 Dr. Reddy's Laboratories SA - 2,272,727 Dr. Reddy's Laboratories Limited - 2,272,727
	(iv) Shared power to dispose or to direct the disposition of: Dr. Reddy's Laboratories, Inc. - None Dr. Reddy's Laboratories SA - None Dr. Reddy's Laboratories Limited - None
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dr. Reddy's Laboratories, Inc.

Signature:	/s/ Stephen Peterson
Name/Title:	Vice President, Head of Finance NAG
Date:	03/12/2026

Dr. Reddy's Laboratories SA

Signature:	/s/ Sameer Natu
Name/Title:	Senior Director - Finance
Date:	03/12/2026

Dr. Reddy's Laboratories Limited

Signature:	/s/ K Randhir Singh
Name/Title:	Company Secretary and Compliance Officer
Date:	03/12/2026

FAQ

What stake does Dr. Reddy's hold in Coya Therapeutics (COYA)?

Dr. Reddy's reports beneficial ownership of 2,272,727 shares, equal to 9.7% of Coya Therapeutics' common stock according to the Schedule 13G filing. The shares are held directly by Dr. Reddy's Laboratories, Inc., with parent entities noted as possibly deemed owners.

Who holds voting and dispositive power over the COYA shares?

The filing states that Dr. Reddy's Laboratories, Inc. has sole voting power and sole dispositive power over 2,272,727 shares. Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories Limited are disclosed as potentially deemed beneficial owners through corporate ownership.

How does the filing calculate the 9.7% ownership percentage?

The 9.7% figure is presented in the Schedule 13G and is based on issuer-reported share counts, including 20,924,456 shares outstanding as of November 10, 2025 and 2,522,727 shares issued and outstanding as of January 29, 2026, as cited in the filing notes.

Does the Schedule 13G indicate an active acquisition or control intent?

The Schedule 13G is a passive ownership disclosure; it does not assert an intent to acquire control. The filing attributes holdings to a wholly-owned subsidiary and notes potential deemed ownership by parent companies, without stating takeover or control actions.

Will this filing force additional disclosures by COYA or Dr. Reddy's?

This Schedule 13G satisfies passive reporting requirements for the current position. Any increase above reporting thresholds or change in intent could trigger amendments or alternative filings; future filings will disclose such changes if they occur.